CSF2 and melanoma: It was first demonstrated to have therapeutic benefits in the Oncovex Pivotal Trial in Melanoma (OPTiM) trial, a phase III randomized controlled trial that compared TVEC to granulocyte–macrophage colony-stimulating factor (GM-CSF) in patients with unresectable stage IIIB to IV melanoma.